SLC5A8, solute carrier family 5 member 8, 160728

N. diseases: 62; N. variants: 1
Disease: Primary malignant neoplasm ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.050 Biomarker group BEFREE This allows for research focused on the potential function of SLC5A8 as a tumour suppressor in CC, and as a biomarker or therapeutic target in this malignancy. 30896789 2019
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.050 Biomarker group BEFREE SLC5A8 is a putative tumor suppressor that is inactivated in more than 10 different types of cancer, but neither the oncogenic signaling responsible for SLC5A8 inactivation nor the functional relevance of SLC5A8 loss to tumor growth has been elucidated. 23918800 2013
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.050 AlteredExpression group BEFREE Vmem hyperpolarization was transduced into downstream events via Vmem-regulated activity of SLC5A8, a sodium-butyrate exchanger previously implicated in human cancer. 23471912 2013
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.050 Biomarker group BEFREE The host conditioning with low-dose basiliximab may augment the efficacy of AIT for cancer using activated autologous lymphocytes. 19148493 2009
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.050 Biomarker group BEFREE SLC5A8-mediated entry of butyrate into cancer cells is associated with inhibition of histone deacetylation. 18661192 2008